Divalproex Sodium Tablet, Delayed Release
Product Images NDC 68180-267

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 68180-267). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (F3c76444 51cb 49f3 81a4 1e0a6f0660f4 01)

Chemical structure of Divalproex Sodium showing its molecular components, including carbon chains, hydroxyl, carboxylate groups, and sodium ion, represented within polymer brackets indicating a repeating unit.*

FDA Label Image

Figure 2 (F3c76444 51cb 49f3 81a4 1e0a6f0660f4 02)

A bar chart comparing percentage values between placebo (PBO) and divalproex sodium (DVPX) groups across two studies (Study 1 using YMRS and Study 2 using MRS). Bars show higher percentages for DVPX in both studies, with Study 1 at 60% and Study 2 at 58%, versus placebo values of 26% and 29%, respectively.*

FDA Label Image

Fig 2 (F3c76444 51cb 49f3 81a4 1e0a6f0660f4 03)

A line graph comparing the percentage reduction in CPS rate between Divalproex Sodium delayed-release tablets and placebo. The x-axis shows the percentage of patients, and the y-axis represents improvement or worsening. The graph illustrates a higher improvement rate for patients taking Divalproex Sodium tablets compared to placebo.*

FDA Label Image

Fig 3 (F3c76444 51cb 49f3 81a4 1e0a6f0660f4 04)

A line graph depicting the percentage reduction in CPS rate among patients at different doses. The x-axis shows the percentage of patients from 0 to 100, and the y-axis represents the percentage reduction in CPS rate from -100% (worsening) to 100% (improvement), with a baseline marked as no change. Two lines are shown: one for high dose (solid line) and one for low dose (dashed line), illustrating patient response distribution by dose.*

FDA Label Image

Figure 4 (F3c76444 51cb 49f3 81a4 1e0a6f0660f4 05)

Bar chart comparing two studies showing values for placebo versus Divalproex Sodium delayed-release tablets. The chart displays height differences in the bars for each category, illustrating the data results for Study 1 and Study 2 groups.*

FDA Label Image

Fig 6 (F3c76444 51cb 49f3 81a4 1e0a6f0660f4 06)

Label for Divalproex Sodium Delayed-Release Tablets USP, 125 mg strength, oral tablet dosage form. The label states each tablet contains 125 mg of valproic acid equivalent. The product is supplied by Lupin Pharmaceuticals, Inc. and manufactured by Lupin Limited in Goa, India. The package size is 100 tablets, and storage and dispensing instructions are provided including temperature guidelines and seal integrity caution.*

FDA Label Image

Fig 7 (F3c76444 51cb 49f3 81a4 1e0a6f0660f4 07)

Label for Divalproex Sodium delayed-release tablets USP, 250 mg strength, in a package of 100 tablets. The label lists Lupin Pharmaceuticals, Inc. as the manufacturer and includes dosage form (delayed-release tablet), storage instructions, and dispensing cautions. The label also displays an NDC number and a barcode.*

FDA Label Image

Figure 8 (F3c76444 51cb 49f3 81a4 1e0a6f0660f4 08)

Label for Divalproex Sodium delayed-release tablets USP, 500 mg strength, manufactured by Lupin Pharmaceuticals, Inc. The label states the product contains 100 tablets, dosage form is delayed-release tablets, and includes storage and dispensing instructions. The label includes barcode and lot/expiration date area.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.